Very good summary! Just to add, while giving growth guidance, management has not considered peptides opportunity so that’s an upside as and when it materialises. Overall, Neuland as a CDMO & API asset should do very well and re-rate further. Quality of business is much higher.
Subscribe To Our Free Newsletter |